Mobilizing the Immune SystemA clinical-stage biopharmaceutical company leveraging from its multiple drug development platforms to treat patients with inflammatory diseases, viral infections, and cancer.
Fighting Inflammatory DiseasesAbivax’s lead candidate ABX464, a potent anti-inflammatory agent, is entering a Phase 2b clinical trial for its potential to bring clinical benefit to patients with ulcerative colitis, and potentially other inflammatory indications.
Developing a Functional Cure for HIVABX464 is a Phase 2 candidate designed to functionally cure HIV by reducing the viral reservoir and is the first ever drug candidate to demonstrate this reduction in patients.
Tackling CancerA small molecule agonist of invariant Natural Killer T-Cells (iNKT) to be tested in Phase 1/2 clinical trial for treatment of hepatocellular carcinoma (HCC).
Abivax is developing therapies that stimulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat ulcerative colitis, HIV, and liver cancer.
Its lead clinical candidate, ABX464, has demonstrated the potential to address indications in two disease areas: treatment of inflammation in ulcerative colitis and reduction of the viral reservoir in HIV.
On November 9, 2018, Abivax hosted a KOL lunch event focused on the mid-stage testing of ABX464 in Ulcerative Colitis and HIV.
With three products in clinical trials and four products in Research and Preclinical development, Abivax’s pipeline is strong and diversified, addressing many unmet needs.
News & Events
Abivax SA has been listed on the Paris stock exchange since June 26, 2015.